Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough

被引：0
|
作者：
Patnaik, Mrinal M. [1 ]
Tefferi, Ayalew [1 ]
机构：
[1] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN 55902 USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷 / 08期
关键词：
REFRACTORY-ANEMIA; RING SIDEROBLASTS;
D O I：
10.1002/ajh.27003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1171 / 1175
页数：5
相关论文
共 50 条
  • [1] Luspatercept in the treatment of lower-risk myelodysplastic syndromes
    Chan, Onyee
    Komrokji, Rami S.
    FUTURE ONCOLOGY, 2021, 17 (12) : 1473 - 1481
  • [2] Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
    Fenaux, Pierre
    Platzbecker, Uwe
    Mufti, Ghulam J.
    Garcia-Manero, Guillermo
    Buckstein, Rena
    Santini, Valeria
    Diez-Campelo, Maria
    Finelli, Carlo
    Cazzola, Mario
    Ilhan, Osman
    Sekeres, Mikkael A.
    Falantes, Jose F.
    Arrizabalaga, Beatriz
    Salvi, Flavia
    Giai, Valentina
    Vyas, Paresh
    Bowen, David
    Selleslag, Dominik
    DeZern, Amy E.
    Jurcic, Joseph G.
    Germing, Ulrich
    Goetze, Katharina S.
    Quesnel, Bruno
    Beyne-Rauzy, Odile
    Cluzeau, Thomas
    Voso, Maria-Teresa
    Mazure, Dominiek
    Vellenga, Edo
    Greenberg, Peter L.
    Hellstrom-Lindberg, Eva
    Zeidan, Amer M.
    Ades, Lionel
    Verma, Amit
    Savona, Michael R.
    Laadem, Abderrahmane
    Benzohra, Aziz
    Zhang, Jennie
    Rampersad, Anita
    Dunshee, Diana R.
    Linde, Peter G.
    Sherman, Matthew L.
    Komrokji, Rami S.
    List, Alan F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (02): : 140 - 151
  • [3] Activity of Luspatercept and ESAs Combination for Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
    Al Ali, Najla
    Luis, Aguirre
    Onyee, Chan
    Kuykendall, Andrew
    Lancet, Jeffrey
    Padron, Eric
    Sallman, David
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S363 - S364
  • [4] Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
    Komrokji, Rami S.
    Aguirre, Luis E.
    Al Ali, Najla H.
    Chan, Onyee
    Xie, Zhuoer
    Kuykendall, Andrew
    Sweet, Kendra
    Lancet, Jeffrey E.
    Padron, Eric
    Sallman, David A.
    BLOOD ADVANCES, 2023, 7 (14) : 3677 - 3679
  • [5] The Effect Of Luspatercept On Erythropoiesis Biomarkers In MEDALIST Trial Patients With Lower-Risk Myelodysplastic Syndromes
    Platzbecker, Uwe
    Zhu, Yiming
    Ha, Xianwei
    Risueno, Alberto
    Chan, Esther
    Zhang, George
    Dunshee, Diana R.
    Acar, Melih
    Shetty, Jeevan K.
    Ito, Rodrigo
    MacBeth, Kyle
    Santini, Valeria
    Garbowski, Maciej W.
    Fenaux, Pierre
    Schwickart, Martin
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 188 - 189
  • [6] Erythropoiesis biomarkers in patients with lower-risk myelodysplastic syndromes treated with luspatercept in the MEDALIST trial
    Platzbecker, U.
    Zhu, Y.
    Ha, X.
    Risueno, A.
    Chan, E.
    Zhang, G.
    Dunshee, D. R.
    Acar, M.
    Shetty, J. K.
    Ito, R.
    MacBeth, K.
    Santini, V
    Garbowski, M. W.
    Fenaux, P.
    Schwickart, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 211 - 213
  • [7] Effect of Luspatercept on Biomarkers of Erythropoiesis in Patients With Lower-Risk Myelodysplastic Syndromes in the MEDALIST Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 13 - 14
  • [8] Lower risk myelodysplastic syndromes
    Angelucci, E.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 44 - 44
  • [9] Luspatercept in Myelodysplastic Syndromes Who and When?
    Komrokji, Rami S.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2020, 34 (02) : 393 - +
  • [10] Treatment patterns and outcomes with luspatercept in patients with lower-risk myelodysplastic syndromes: A retrospective US cohort analysis
    Mukherjee, Sudipto
    Brown-Bickerstaff, Cherrishe
    Falkenstein, Angelica
    Makinde, Adeola Y.
    Bland, Emily
    Laney, Jalyna
    Garretson, Marne
    Huggar, David
    Mcbride, Ali
    HEMASPHERE, 2024, 8 (01):
12345